Velocity
This Week's Stories
Form Bio

Form Bio

Biotech · AI · Genetic Medicine

Acquisition

Astromech buys fellow Colossal spinoff Form Bio for $230M in stock

November 17, 2026

Deal Value

$230M

Pairing evolutionary AI with genetic-medicine design tools lets researchers catch quality flaws earlier, cutting costly downstream purification.

  • Astromech, an AI company that models biological change, acquired fellow Colossal Biosciences spinoff Form Bio in an all-stock deal valued at $230 million.
  • Both companies spun out of Colossal Biosciences, the de-extinction startup co-founded by Ben Lamm and Harvard geneticist George Church; Astromech builds predictive evolutionary models while Form Bio designs and tests genetic medicines.
  • Form Bio co-founder and former CEO Andrew Busey becomes Astromech's chief AI officer and head of technology, and Astromech retained Form Bio's AI, engineering and product teams.
  • Astromech was valued at $3.8 billion as of August and has raised more than $60 million total, including a $20 million round led by Arch Venture Partners; Form Bio had raised over $40 million since launching in 2022.
  • Form Bio's design tools already support genetic-medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies and Solid Biosciences.
  • Astromech plans to raise a new funding round next year, CEO Ben Lamm told Axios.
  • The deal reflects a broader trend of AI and biotech firms acquiring computational-biology teams and tools to build integrated research platforms rather than buy drug pipelines.

Read More About This Story

Get the app

Stay Ahead With Velocity

Deep company profiles, investor context, and every original source behind this story — plus the next one, the moment it breaks.

Download on the App StoreGet it on Google Play

More This Week

View All →